SCHEMBL349053

SCHEMBL349053

OCC1CCN(Cc2ccccc2)CC1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 1/20 0.71
CXCR4 P61073 1/20 0.66
ACHE P22303 3/20 0.62
ALDH1A1 P00352 2/20 0.61
SIGMAR1 Q99720 2/20 0.61
BCHE P06276 2/20 0.59
DRD2 P14416 2/20 0.57
DRD4 P21917 1/20 0.57
DRD3 P35462 1/20 0.57
LTA4H P09960 2/20 0.57
KDM4E B2RXH2 1/20 0.56
GLA P06280 1/20 0.56
GAA P10253 1/20 0.56
MAPT P10636 1/20 0.56
HTT P42858 1/20 0.56
ATM Q13315 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
HTR2A P28223 1/20 0.56
HTR2C P28335 1/20 0.56
HTR2B P41595 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10385903 0.98 CCR3 (0.69) CCR3CXCR4ACHEALDH1A1SIGMAR1
SCHEMBL8545766 0.89 CYP2D6 (0.68) CCR3CXCR4ACHEALDH1A1SIGMAR1
SCHEMBL5968994 0.89 CYP2D6 (0.68) CCR3CXCR4ACHEALDH1A1SIGMAR1
SCHEMBL1386235 0.89 CYP2D6 (0.68) CCR3CXCR4ACHEALDH1A1SIGMAR1
SCHEMBL368874 0.86 CCR3 (0.67) CCR3CXCR4ACHEALDH1A1BCHE
Oxalic Acid SCHEMBL10461399 0.84 CYP2D6 (0.66) CCR3CXCR4ACHEALDH1A1BCHE
SCHEMBL5640368 0.83 CYP2D6 (0.65) CCR3ALDH1A1SIGMAR1DRD4
SCHEMBL2004615 0.83 CCR3 (1.00) CCR3ACHEALDH1A1SIGMAR1KDM4E
SCHEMBL4433102 0.83 CCR3 (0.73) CCR3CXCR4ACHEALDH1A1SIGMAR1
SCHEMBL15140944 0.83 CCR3 (0.73) CCR3CXCR4ACHEALDH1A1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117924153-A Preparation method of key intermediate of donepezil bulk drug 山东盛安贝新材料有限公司南京分公司 2024-04-26 CN claimed
CN-111499559-B Method for synthesizing donepezil in water 南京理工大学 2022-03-15 CN claimed
CN-113979922-A Preparation method of N-benzylpiperidine-4-formaldehyde and N-benzylpiperidine-4-methanol 新发药业有限公司 2022-01-28 CN claimed
CN-111499559-A Method for synthesizing donepezil in water 南京理工大学 2020-08-07 CN claimed
CN-107903204-B Synthesis method of donepezil 郑州大学 2020-07-03 CN claimed
WO-2012038966-A1 PROCESS FOR THE PREPARATION OF DONEPEZIL INTERMEDIATE TYCHE INDUSTRIES LTD. (IN) 2012-03-29 WO claimed
EP-4606803-A1 KRAS G12D DEGRADATION AGENT, AND PREPARATION METHOD AND USE THEREFOR Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. (CN) 2025-08-27 EP disclosed
US-12251370-B2 Small molecule inhibitors of the BfrB:Bfd interaction BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2025-03-18 US disclosed
CN-118930415-A Rare earth catalytic ketone alpha-alkylation method 复旦大学 2024-11-12 CN disclosed
CN-117924153-A Preparation method of key intermediate of donepezil bulk drug 山东盛安贝新材料有限公司南京分公司 2024-04-26 CN disclosed
WO-2024083258-A1 KRAS G12C DEGRADATION AGENT, AND PREPARATION METHOD AND USE THEREFOR 上海领泰生物医药科技有限公司 2024-04-25 WO disclosed
CN-117917416-A KRAS G12D degradation agent and preparation method and application thereof 上海领泰生物医药科技有限公司 2024-04-23 CN disclosed
EP-3440087-B1 THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS MANKIND PHARMA LTD (IN) 2022-08-10 EP disclosed
EP-0501322-A1 3-Piperidinylmethylcarboxylate substituted indoles GLAXO GROUP LIMITED (GB) 1992-09-02 EP disclosed
US-5116846-A N-ARALKYL PIPERIDINE DERIVATIVES AS PSYCHOTROPIC DRUGS DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1992-05-26 US disclosed
EP-0449186-A2 N-aralkyl piperidine derivatives as psychotropic drugs THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1991-10-02 EP disclosed
EP-0449187-A2 Piperidin ether derivatives as psychotropic drugs or plant fungicides THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1991-10-02 EP disclosed
US-4647565-A 2-(2-quinazolinylaminoalkoxymethyl)-1,4-dihydropyridine derivatives as cardiovascular agents PFIZER INC. (US) 1987-03-03 US disclosed
EP-0168151-A1 Dihydropyridine cardiovascular agents Pfizer Limited (GB) 1986-01-15 EP disclosed
US-4246262-A ANTIBIOTICS LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) 1981-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12251370-B2 Small molecule inhibitors of the BfrB:Bfd interaction BLVRB, TFPI, ETFB CCR3 4523/4885CXCR4 3604/4885ACHE 4279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.